Rapid Micro Biosystems Inc (RPID) - Net Assets
Based on the latest financial reports, Rapid Micro Biosystems Inc (RPID) has net assets worth $33.21 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($74.85 Million) and total liabilities ($41.65 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Rapid Micro Biosystems Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $33.21 Million |
| % of Total Assets | 44.36% |
| Annual Growth Rate | N/A |
| 5-Year Change | -84.97% |
| 10-Year Change | N/A |
| Growth Volatility | 330.89 |
Rapid Micro Biosystems Inc - Net Assets Trend (2010–2025)
This chart illustrates how Rapid Micro Biosystems Inc's net assets have evolved over time, based on quarterly financial data. Also explore Rapid Micro Biosystems Inc asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Rapid Micro Biosystems Inc (2010–2025)
The table below shows the annual net assets of Rapid Micro Biosystems Inc from 2010 to 2025. For live valuation and market cap data, see Rapid Micro Biosystems Inc (RPID) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $33.21 Million | -55.93% |
| 2024-12-31 | $75.35 Million | -36.14% |
| 2023-12-31 | $117.99 Million | -28.13% |
| 2022-12-31 | $164.17 Million | -25.71% |
| 2021-12-31 | $220.98 Million | +790.33% |
| 2020-12-31 | $24.82 Million | +3523.45% |
| 2019-12-31 | $-725.00K | +85.98% |
| 2011-12-31 | $-5.17 Million | -91.38% |
| 2010-12-31 | $-2.70 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Rapid Micro Biosystems Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 52239700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $445.00K | 1.34% |
| Other Comprehensive Income | $11.00K | 0.03% |
| Other Components | $555.15 Million | 1671.83% |
| Total Equity | $33.21 Million | 100.00% |
Rapid Micro Biosystems Inc Competitors by Market Cap
The table below lists competitors of Rapid Micro Biosystems Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Prime Securities Limited
NSE:PRIMESECU
|
$103.66 Million |
|
Piscines Desjoyaux SA
PA:ALPDX
|
$103.67 Million |
|
Scope Fluidics SA
WAR:SCP
|
$103.68 Million |
|
Tethys Petroleum Ltd
V:TPL
|
$103.70 Million |
|
09women Co. Ltd.
KQ:366030
|
$103.63 Million |
|
SDI Ltd
AU:SDI
|
$103.62 Million |
|
Synchronoss Technologies Inc
NASDAQ:SNCR
|
$103.56 Million |
|
CHINA NEW CITY COMM.
F:C7B
|
$103.55 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Rapid Micro Biosystems Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 75,352,000 to 33,206,000, a change of -42,146,000 (-55.9%).
- Net loss of 47,123,000 reduced equity.
- Share repurchases of 162,000 reduced equity.
- Other comprehensive income decreased equity by 28,000.
- Other factors increased equity by 5,167,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-47.12 Million | -141.91% |
| Share Repurchases | $162.00K | -0.49% |
| Other Comprehensive Income | $-28.00K | -0.08% |
| Other Changes | $5.17 Million | +15.56% |
| Total Change | $- | -55.93% |
Book Value vs Market Value Analysis
This analysis compares Rapid Micro Biosystems Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.40x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.02 | $2.53 | x |
| 2020-12-31 | $0.64 | $2.53 | x |
| 2021-12-31 | $5.33 | $2.53 | x |
| 2022-12-31 | $3.87 | $2.53 | x |
| 2023-12-31 | $2.74 | $2.53 | x |
| 2024-12-31 | $1.73 | $2.53 | x |
| 2025-12-31 | $0.74 | $2.53 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Rapid Micro Biosystems Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -141.91%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -140.30%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 2.25x
- Recent ROE (-141.91%) is below the historical average (-66.90%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -128.22% | 0.52x | 0.00x | $-21.10 Million |
| 2020 | -149.39% | -230.63% | 0.23x | 2.82x | $-39.56 Million |
| 2021 | -33.27% | -316.48% | 0.10x | 1.09x | $-95.62 Million |
| 2022 | -37.04% | -354.91% | 0.09x | 1.16x | $-77.22 Million |
| 2023 | -44.47% | -232.99% | 0.16x | 1.22x | $-64.27 Million |
| 2024 | -62.23% | -167.16% | 0.29x | 1.30x | $-54.42 Million |
| 2025 | -141.91% | -140.30% | 0.45x | 2.25x | $-50.44 Million |
Industry Comparison
This section compares Rapid Micro Biosystems Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,432,799,891
- Average return on equity (ROE) among peers: -74.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Rapid Micro Biosystems Inc (RPID) | $33.21 Million | 0.00% | 1.25x | $103.64 Million |
| Abbott Laboratories (ABT) | $24.16 Billion | 9.46% | 0.81x | $155.56 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-13.54K | 0.00% | 0.00x | $21.60 Million |
| Aethlon Medical Inc (AEMD) | $9.29 Million | -84.45% | 0.15x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $105.73 Million | -116.68% | 0.61x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $2.15 Million | -112.84% | 0.45x | $16.04 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $8.60 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $4.22 Million |
| Artivion Inc (AORT) | $89.39 Million | 8.74% | 0.25x | $1.73 Billion |
| Apyx Medical Inc (APYX) | $21.15 Million | 2.82% | 0.30x | $125.55 Million |
About Rapid Micro Biosystems Inc
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biologics, medical devices, and personal care products in the United States, Switzerland, Germany, Japan, and internationally. The company offers Growth Direct platform, which includes growth direct system, proprietary consumables, … Read more